-
Ukoniq Drug Recall in April 2022 Comes Soon After FDA Warning About Increased Risk of Death in February 2022
This "New" Lymphoma Drug Had Only Been on the Market Since February 2021, When Ukoniq Received FDA Accelerated Approval (Posted by Tom Lamb at Drug Injury Watch) In February 2022 we wrote about this Drug…
-
Multiple Sclerosis (MS) Drugs Gilenya and Ocrevus Associated With a Higher Likelihood of Melanoma Skin Cancer
Other MS Treatments Such as Lemtrada and Mayzent May Have an Increased Risk of Basal Cell Carcinoma and Squamous Cell Carcinoma (Posted by Tom Lamb at Drug Injury Watch) An analysis of skin cancers reported…
-
Ukoniq FDA Advisory Committee Meeting in April 2022 Will Evaluate Ukoniq Drug Safety Findings
FDA Has Been Investigating Ukoniq for an Increased Risk of Death in Lymphoma Cancer Patients Treated With Ukoniq (Posted by Tom Lamb at Drug Injury Watch) UPDATE: Ukoniq Drug Recall in April 2022 Comes Soon After…
-
How People Can Report Adverse Drug Reactions to the FDA, and What Happens to This Information Thereafter
From time to time we hear from people who want to know: (1) How they can report a serious prescription drug side effect, or adverse drug reaction, to the FDA; and, (2) What happens…